# Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

> **NCT02001974** · PHASE1 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel+Reparixin

## Key facts

- **NCT ID:** NCT02001974
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-27
- **Primary completion:** 2014-06-25
- **Final completion:** 2015-01-15
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001974, "Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02001974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*